In Pursuit of Functional Electrospun Materials for Clinical Applications in Humans

Stoddard, Ryan J.; Steger, Arielle L; Blakney, Anna K.; Woodrow, Kim A.

doi:10.4155/tde-2016-0017

Cited by 31 publications

(32 citation statements)

References 142 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, more and more attention has been paid to the production of electrospun nanofibers for commercial development, with many exciting developments in scale-up technologies which should lead in the coming years to the preparation of electrospun ASDs on the industrial scale and products emerging on the market. Clinical investigations of the fiber-based ASDs are also expected to accelerate in the coming years [301][302][303]. There remain however a number of challenges in In translating electrospun nanofibers from the research laboratory to the clinic.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Electrospun amorphous solid dispersions of poorly water-soluble drugs: A review

Williams

et al. 2018

Journal of Controlled Release

232

156

View full text Add to dashboard Cite

The development of oral dosage forms for poorly water-soluble active pharmaceutical ingredients (APIs) is a persistent challenge. A range of methods has been explored to address this issue, and amorphous solid dispersions (ASDs) have received increasing attention. ASDs are typically prepared by starting with a liquid precursor (a solution or melt) and applying energy for solidification. Many techniques can be used, with the emergence of electrospinning as a potent option in recent years. This method uses electrical energy to induce changes from liquid to solid. Through the direct applications of electrical energy, electrospinning can generate nanofiber-based ASDs from drug-loaded solutions, melts and melt-solutions. The technique can also be combined with other approaches using the application of mechanical, thermal or other energy sources. Electrospinning has numerous advantages over other approaches to produce ASDs. These advantages include extremely rapid drying speeds, ease of implentation, compatibility with a wide range of active ingredients (including those which are thermally labile), and the generation of products with large surface areas and high porosity. Furthermore, this technique exhibits the potential to create so-called 'fifth-generation' ASDs with nanostructured architectures, such as core/shell or Janus systems and their combinations. These advanced systems can improve dissolution behaviour and provide programmable drug release profiles. Additionally, the fiber components and their spatial distributions can be precisely controlled. Electrospun fiber-based ASDs can maintain an incorporated active ingredient in the amorphous physical form for prolonged periods of time because of their homogeneous drug distribution within the polymer matrix (typically they comprise solid solutions), and ability to inhibit molecular motion. These ASDs can be utilised to generate oral dosage forms for poorly water-soluble drugs, resulting in linear or multiple-phase release of one or more APIs. Electrospun ASDs can also be exploited as templates for manipulating molecular self-assembly, offering a bridge between ASDs and other types of dosage forms. This review addresses the development, advantages and pharmaceutical applications of electrospinning for producing polymeric ASDs. Material preparation and analysis procedures are considered. The mechanisms through which performance has been improved are also discussed.

show abstract

Section: Accepted Manuscriptmentioning

confidence: 99%

Electrospun amorphous solid dispersions of poorly water-soluble drugs: A review

Williams

et al. 2018

Journal of Controlled Release

232

156

View full text Add to dashboard Cite

show abstract

“…Unlike the traditional electrospinning process that requires highly viscous solutions, the emulsion electrospinning can produce optimal nanofibers using dilute polymer solutions and polymers of low molecular weight [63]. Despite the emulsion electrospinning method requiring the same basic set up as conventional electrospinning [30,63], this technique has been applied to engineer core-shell structured nanofibers [66]. The drug and polymer are dissolved in the appropriated solvents, eliminating the need for a common solvent [54].…”

Section: Composition Natural (Nt)mentioning

confidence: 99%

“…The drug and polymer are dissolved in the appropriated solvents, eliminating the need for a common solvent [54]. Encapsulating bioactive agents in the core using water/oil phase or oil/water phase (W/O or O/W) emulsions prevents the side-effects associated with organic solvents contact, one of the major contributors to bioactive agents denaturation [66]. Hence, through encapsulation, the biological agent is protected in the core fiber and its release rate can be managed by controlling the structure and composition of the shell [66,67].…”

Section: Composition Natural (Nt)mentioning

confidence: 99%

Poly(Vinyl Alcohol)-Based Nanofibrous Electrospun Scaffolds for Tissue Engineering Applications

2019

View full text Add to dashboard Cite

Tissue engineering (TE) holds an enormous potential to develop functional scaffolds resembling the structural organization of native tissues, to improve or replace biological functions and prevent organ transplantation. Amongst the many scaffolding techniques, electrospinning has gained widespread interest because of its outstanding features that enable the production of non-woven fibrous structures with a dimensional organization similar to the extracellular matrix. Various polymers can be electrospun in the form of three-dimensional scaffolds. However, very few are successfully processed using environmentally friendly solvents; poly(vinyl alcohol) (PVA) is one of those. PVA has been investigated for TE scaffolding production due to its excellent biocompatibility, biodegradability, chemo-thermal stability, mechanical performance and, most importantly, because of its ability to be dissolved in aqueous solutions. Here, a complete overview of the applications and recent advances in PVA-based electrospun nanofibrous scaffolds fabrication is provided. The most important achievements in bone, cartilage, skin, vascular, neural and corneal biomedicine, using PVA as a base substrate, are highlighted. Additionally, general concepts concerning the electrospinning technique, the stability of PVA when processed, and crosslinking alternatives to glutaraldehyde are as well reviewed.

show abstract

“…Nevertheless, there is still a great gap between the lab validation to clinical trials and then the actual commercialization. Currently, no electrospun products have been approved by FDA and only few clinical trials have been documented to further testify the function of the designed drug delivery platforms . In a double‐blind, randomized and placebo‐controlled clinical trial of Pathon, a NO releasing PU patch, no sufficient efficacy was observed compared to standard treatment .…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Electrospun Fibrous Architectures for Drug Delivery, Tissue Engineering and Cancer Therapy

Ding

Zhang

et al. 2018

Adv Funct Materials

196

138

View full text Add to dashboard Cite

The versatile electrospinning technique is recognized as an efficient strategy to deliver active pharmaceutical ingredients and has gained tremendous progress in drug delivery, tissue engineering, cancer therapy, and disease diagnosis. Numerous drug delivery systems fabricated through electrospinning regarding the carrier compositions, drug incorporation techniques, release kinetics, and the subsequent therapeutic efficacy are presented herein. Targeting for distinct applications, the composition of drug carriers vary from natural/synthetic polymers/blends, inorganic materials, and even hybrids. Various drug incorporation approaches through electrospinning are thoroughly discussed with respect to the principles, benefits, and limitations. To meet the various requirements in actual sophisticated in vivo environments and to overcome the limitations of a single carrier system, feasible combinations of multiple drug-inclusion processes via electrospinning could be employed to achieve programmed, multi-staged, or stimuli-triggered release of multiple drugs. The therapeutic efficacy of the designed electrospun drugeluting systems is further verified in multiple biomedical applications and is comprehensively overviewed, demonstrating promising potential to address a variety of clinical challenges.

show abstract

In Pursuit of Functional Electrospun Materials for Clinical Applications in Humans

Cited by 31 publications

References 142 publications

Electrospun amorphous solid dispersions of poorly water-soluble drugs: A review

Electrospun amorphous solid dispersions of poorly water-soluble drugs: A review

Poly(Vinyl Alcohol)-Based Nanofibrous Electrospun Scaffolds for Tissue Engineering Applications

Electrospun Fibrous Architectures for Drug Delivery, Tissue Engineering and Cancer Therapy

Contact Info

Product

Resources

About